Abstracted Scientific Content

Barriers to generics policy reform: a US case study

Published in: Volume 7 / Year 2018 / Issue 1
Author(s):
Page: 48

Submitted: 29 December 2017; Revised: 5 January 2018; Accepted: 12 January 2018; Published online first: 19 January 2018 A recent comparison of generic drug markets [1] explores the history of… Read More »

A comparison of European and US generic drug markets

Published in: Volume 6 / Year 2017 / Issue 4
Author(s):
Page: 190-2

Submitted: 19 June 2017; Revised: 5 September 2017; Accepted: 6 September 2017; Published online first: 19 September 2017 Introduction Comparative research on the European and US generic drug markets based… Read More »

Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar

Published in: Volume 6 / Year 2017 / Issue 4
Author(s):
Page: 188-9

Submitted: 17 November 2017; Revised: 20 November 2017; Accepted: 22 November 2017; Published online first: 5 December 2017 The tumour necrosis factor (TNF) inhibitor infliximab is known to significantly improve… Read More »

‘To prescribe generics is to play with the life of the patient’: misconceptions of generics in Guatemala

Published in: Volume 6 / Year 2017 / Issue 3
Author(s):
Page: 147-8

Submitted: 13 September 2017; Revised: 17 September 2017; Accepted: 18 September 2017; Published online first: 25 September 2017 Both pharmacists and doctors in Guatemala lack trust in generic medicines, according… Read More »

Effective generics substitution

Published in: Volume 6 / Year 2017 / Issue 2
Author(s):
Page: 100

Submitted: 19 January 2017; Revised: 20 January 2017; Accepted: 23 January 2017; Published online first: 6 February 2017 In an article published in US Pharmacist [1] Manigault et al. emphasize… Read More »

Generic prices estimated for four novel cancer drugs

Published in: Volume 6 / Year 2017 / Issue 2
Author(s):
Page: 99-100

Submitted: 13 March 2017; Revised: 15 March 2017; Accepted: 16 March 2017; Published online first: 29 March 2017 Generic drug manufacturing of four major cancer drugs could massively reduce their… Read More »

Strategies used to delay or prevent access to affordable generic drugs in the US

Published in: Volume 5 / Year 2016 / Issue 4
Author(s):
Page: 188

Submitted: 28 November 2016; Revised: 29 November 2016; Accepted: 30 November 2016; Published online first: 5 December 2016 In the journal Blood, Jones et al. [1] discuss strategies used by… Read More »

An empirical study of market-based purchasing policies for generic pharmaceuticals in Sweden

Published in: Volume 5 / Year 2016 / Issue 4
Author(s):
Page: 187

Submitted: 1 December 2016; Revised: 6 December 2016; Accepted: 7 December 2016; Published online first: 12 December 2016 In Sweden, the government funds an insurance programme covering 75–80% of the… Read More »

Essential information for internists on biologicals and biosimilars

Published in: Volume 5 / Year 2016 / Issue 4
Author(s):
Page: 186-7

Submitted: 21 November 2016; Revised: 22 November 2016; Accepted: 24 November 2016; Published online first: 30 November 2016 Authors from the IRCCS – Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan,… Read More »

Effect of naming on pharmacists’ perceptions and dispensing of biosimilars

Published in: Volume 5 / Year 2016 / Issue 4
Author(s):
Page: 185

Submitted: 21 November 2016; Revised: 22 November 2016; Accepted: 24 November 2016; Published online first: 30 November 2016 A study of pharmacists investigated their perceptions of biosimilar naming conventions and… Read More »

Page 1 of 3 1 2 3 Next »
Go Back Print